Senior Scientist
Erik Paus is a seasoned professional in the biotechnology and pharmaceutical industries, bringing over 40 years of experience spanning basic research, regulatory affairs, and business development. His career has ranged from launching biotech start-ups to holding key roles at global Fortune 500 life science companies. Erik began his scientific career at the New England Enzyme Center in Boston, focusing on molecular biology, fermentation, and protein purification. Notably, his research contributed to the understanding of the innate immune system of the horseshoe crab (Limulus polyphemus), including the discovery of proteins with potential anti-sepsis applications.
Erik has extensively collaborated with regulatory bodies such as the FDA and the U.S. Pharmacopeia (USP). In 2007, he founded Coastal BioPharm, LLC, a firm dedicated to advancing opportunities in regenerative medicine, with a focus on tissue engineering, biomaterials, and stem cell culture. Known for his strategic vision and customer-driven approach, Erik brings deep technical knowledge and international experience in sales, market development, and regulatory strategy.